We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+17.33%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$673M
AUM Growth
+$87.3M
Cap. Flow
+$52.4M
Cap. Flow %
7.78%
Top 10 Hldgs %
60.63%
Holding
55
New
16
Increased
9
Reduced
7
Closed
18

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$37.4M
2
EXEL icon
Exelixis
EXEL
+$24.9M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$20M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$16.9M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$32.9M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$17.3M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$15M
4
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$13.8M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 83.75%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
51
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-75,000
Closed -$9.9M
DERM
52
DELISTED
Dermira, Inc.
DERM
– –
-43,637
Closed -$1.21M
CNXR
53
DELISTED
Connecture, Inc.
CNXR
– –
-4,127,232
Closed -$660K
BHVN
54
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-500,192
Closed -$13.5M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Great Point Partners held 55 positions worth $673M, up 15% from $586M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Great Point Partners deployed $52.4M of net new capital in Q1 2018, opening 16 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 500,000 shares worth $34M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 87% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lumos Pharma, Inc. Common Stock, an estimated $13.8M trimmed.

  • Great Point Partners's largest Q1 2018 buy was Puma Biotechnology: 500,000 shares worth $34M.
  • Great Point Partners added most to Iovance Biotherapeutics in Q1 2018, an estimated $20M increase.
  • Great Point Partners's biggest Q1 2018 reduction was Lumos Pharma, Inc. Common Stock, cutting an estimated $13.8M.
  • Great Point Partners fully exited Sage Therapeutics in Q1 2018, selling an estimated $32.9M.
  • Great Point Partners's ten largest holdings make up 61% of its $673M portfolio in Q1 2018.
  • Great Point Partners opened 16 new positions and closed 18 in Q1 2018.
  • Great Point Partners's portfolio value rose 15% quarter-over-quarter to $673M.

Based on Great Point Partners's 13F filing for Q1 2018, filed 14 May 2018.